Our resource hub to discover reports, policy papers and other forms of informative content
This policy note characterizes Canada’s current testing infrastructure and its limitations, which include that it hinders current and future patient access to the best available treatments….
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…
Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment….
Informative content to keep you up to date on the most pressing issues facing our industry.
